Lucia Santome
Overview
Explore the profile of Lucia Santome including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agraso S, Lazaro M, Firvida X, Santome L, Fernandez N, Azpitarte C, et al.
Cancer Treat Res Commun
. 2022 Nov;
33:100646.
PMID: 36335799
Background: In clinical studies, first-line afatinib demonstrated efficacy in Del19-EGFR NSCLC. Materials And Methods: This prospective, non-interventional study assessed efficacy and safety of first-line afatinib in patients with advanced/metastatic NSCLC...
2.
Ruiz-Banobre J, Areses-Manrique M, Mosquera-Martinez J, Cortegoso A, Afonso-Afonso F, de Dios-Alvarez N, et al.
Transl Lung Cancer Res
. 2020 Feb;
8(6):1078-1085.
PMID: 32010585
The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 (PD-1) or...
3.
Garcia J, Santome L, Anido U, Fernandez-Calvo O, Afonso-Afonso J, Lazaro M, et al.
Curr Oncol Rep
. 2016 Nov;
18(12):72.
PMID: 27812861
Once metastatic bladder cancer has progressed to first-line treatment, the number of therapeutic options is scarce. Among chemotherapeutic agents showing activity in phase II trials, including taxanes, vinflunine (VFL) is...
4.
Sanchez-Ares M, Cameselle-Teijeiro J, Vazquez-Estevez S, Lazaro-Quintela M, Vazquez-Boquete A, Afonso-Afonso F, et al.
Oncol Lett
. 2016 Jul;
12(2):1403-1407.
PMID: 27446444
Identification of anaplastic lymphoma receptor tyrosine kinase () gene rearrangements is a standard diagnostic test in patients with advanced non-small cell lung cancer (NSCLC). The current study describes the experience...
5.
Vazquez S, Casal J, Afonso Afonso F, Firvida J, Santome L, Baron F, et al.
Cancer Manag Res
. 2016 Feb;
8:11-20.
PMID: 26893581
Purpose: This study aimed to assess the incidence of mutations in the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) patients in the Galician region of Spain...
6.
Lazaro Quintela M, Leon Mateos L, Estevez S, Fernandez Calvo O, Herranz U, Afonso Afonso F, et al.
Cancer Treat Rev
. 2015 Feb;
41(3):247-53.
PMID: 25638257
Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer (mCRPC) who progressed to docetaxel. The...
7.
Vazquez S, Lazaro M, Firvida J, Santome L, Afonso J, Amenedo M, et al.
Anticancer Drugs
. 2014 Jan;
25(4):368-74.
PMID: 24384805
After progression during first-line treatment in advanced non-small-cell lung cancer (NSCLC), a large percentage of patients are candidates for second-line treatment. The majority do not have epidermal growth factor receptor-activating...
8.
Leon L, Vazquez S, Gracia J, Casal J, Lazaro M, Firvida J, et al.
Expert Opin Pharmacother
. 2012 May;
13(10):1389-96.
PMID: 22630129
Objective: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC)....